Mounjaro can boost weight loss in people without diabetes
People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...
Ever-Growing USA on MSN22h
Retratutide: Eli Lilly’s Groundbreaking Drug Poised to Transform Obesity and Diabetes Treatment
In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...
Medscape23h
Significant Improvement in Psoriasis Observed With Novel Oral Drug Icotrokinra, in Phase 3 Trial
Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.
GlobalData on MSN17h
Incyte stock hit 11% despite paediatric dermatology trials hitting target
The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.
Eli Lilly: A Safe Harbor Amid Market Volatility
Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...